Unknown PHASE3 INTERVENTIONAL 2-arm NCT02453893

Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

Double-blind,Double-simulation,Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions Schizophrenia

Interventions Iloperidone Risperidone

Updated 6 times since 2017 Last updated: May 26, 2015 Started: Nov 30, 2013 Primary completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Schizophrenia, this trial is ongoing. The trial is conducted by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. and has accumulated 6 data snapshots since 2013. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
May 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Recruiting PHASE3

First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Data source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China